Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6413]

Draft guidance: 1

Draft guidance (downloadable version) (PDF 310 KB)

Draft guidance (online commenting)

Committee papers (PDF 8.16 MB)

Public committee slides (PDF 1.67 MB)

Final scope (PDF 155 KB)

Final stakeholder list (PDF 154 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 252 KB)

Provisional stakeholder list post referral (PDF 150 KB)